Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Net Cash Flow data on record, last reported at $15.8 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 480.58% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $19.1 million, up 126.87%, while the annual FY2025 figure was $19.1 million, 126.87% up from the prior year.
  • Net Cash Flow reached $15.8 million in Q4 2025 per CCCC's latest filing, up from -$19.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $184.9 million in Q2 2021 and bottomed at -$118.4 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$5.3 million, with a median of -$6.2 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 420.04% in 2021, then skyrocketed 480.58% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$84.6 million in 2021, then surged by 76.6% to -$19.8 million in 2022, then skyrocketed by 431.4% to $65.6 million in 2023, then tumbled by 106.33% to -$4.1 million in 2024, then surged by 480.58% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $15.8 million in Q4 2025, -$19.3 million in Q3 2025, and $26.9 million in Q2 2025.